Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

2017399 citationsJournal Articlebronze Open Access

Authors

Eli L. Diamond · Cornell University

Vivek Subbiah · The University of Texas MD Anderson Cancer Center

A. Craig Lockhart · University of Miami

Jean‐Yves Blay · Centre Léon Bérard

Igor Puzanov · Roswell Park Comprehensive Cancer Center

Ian Chau · Royal Marsden Hospital

Noopur Raje

Abstract

In this study, vemurafenib had prolonged efficacy in patients with BRAF V600-mutant ECD and LCH and warrants consideration as a new standard of care for these patients.

Topics & Keywords

Histiocytic Disorders and Treatments Vascular Malformations and Hemangiomas Tumors and Oncological Cases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Oncology

Volume 4, Issue 3, pp. 384-384

DOI: 10.1001/jamaoncol.2017.5029

Field-Weighted Citation Impact: 21.46